VORICONAZOLE WOCKHARDT voriconazole 200 mg powder for injection vial Australija - engleski - Department of Health (Therapeutic Goods Administration)

voriconazole wockhardt voriconazole 200 mg powder for injection vial

wockhardt bio pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: sodium chloride; hydroxypropylbetadex - voriconazole wockhardt is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

VORIWOK voriconazole 200 mg powder for injection vial Australija - engleski - Department of Health (Therapeutic Goods Administration)

voriwok voriconazole 200 mg powder for injection vial

wockhardt bio pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: sodium chloride; hydroxypropylbetadex - voriwok is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

ADCETRIS brentuximab vedotin (rch) 50 mg powder for injection vial Australija - engleski - Department of Health (Therapeutic Goods Administration)

adcetris brentuximab vedotin (rch) 50 mg powder for injection vial

takeda pharmaceuticals australia pty ltd - brentuximab vedotin, quantity: 50 mg - injection, powder for - excipient ingredients: citric acid monohydrate; trehalose dihydrate; sodium citrate dihydrate; polysorbate 80 - hodgkin lymphoma,treatment of patients with previously untreated cd30+ stage iii or stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine, and dacarbazine (avd).,treatment of adult patients with cd30+ hl at higher risk of relapse or progression following asct.,treatment of adult patients with relapsed or refractory cd30+ hl:,1. following autologous stem cell transplant (asct) or,2. following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option.,peripheral t-cell lymphoma,treatment of adult patients with previously untreated cd30+ peripheral t-cell lymphoma (ptcl) in combination with cyclophosphamide, doxorubicin, and prednisone (chp).,treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (salcl).,cutaneous t cell lymphoma,treatment of adult patients with cd30+ cutaneous t-cell lymphoma (ctcl) after at least 1 prior systemic therapy.

VORICONAZOLE-AFT voriconazole 200 mg powder for injection vial Australija - engleski - Department of Health (Therapeutic Goods Administration)

voriconazole-aft voriconazole 200 mg powder for injection vial

aft pharmaceuticals pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: nitrogen; water for injections; sulfobutyl betadex sodium - voriconazole ? aft is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

FEIBA 50units/ml (1,000unit) powder and 20ml solvent for solution for infusion vials Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

feiba 50units/ml (1,000unit) powder and 20ml solvent for solution for infusion vials

1,000unit) powder and 20ml solvent for solution for infusion vials (takeda uk ltd - factor viii inhibitor bypassing fraction - powder and solvent for solution for infusion - 1000unit

VORICONAZOLE KABI voriconazole 200 mg powder for injection vial Australija - engleski - Department of Health (Therapeutic Goods Administration)

voriconazole kabi voriconazole 200 mg powder for injection vial

fresenius kabi australia pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: arginine; sodium hydroxide; dilute hydrochloric acid; hydroxypropylbetadex - voriconazole is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp. and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

BREVIBLOC esmolol hydrochloride 2.5 g powder for injection for infusion vial Australija - engleski - Department of Health (Therapeutic Goods Administration)

brevibloc esmolol hydrochloride 2.5 g powder for injection for infusion vial

phebra pty ltd - esmolol hydrochloride, quantity: 2500 mg - injection, powder for - excipient ingredients: - supraventricular tachycardia,brevibloc (esmolol hcl) is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. brevibloc is also indicated in non compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. brevibloc is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

Zepraxen 350mg powder for solution for injection/infusion Malta - engleski - Medicines Authority

zepraxen 350mg powder for solution for injection/infusion

vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - daptomycin - powder for solution for injection/infusion - daptomycin 350 mg - antibacterials for systemic use

Zepraxen 500mg powder for solution for injection/infusion Malta - engleski - Medicines Authority

zepraxen 500mg powder for solution for injection/infusion

vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - daptomycin - powder for solution for injection/infusion - daptomycin 500 mg - antibacterials for systemic use

REMIFENTANIL SANDOZ remifentanil (as hydrochloride) 5mg powder for injection vial Australija - engleski - Department of Health (Therapeutic Goods Administration)

remifentanil sandoz remifentanil (as hydrochloride) 5mg powder for injection vial

sandoz pty ltd - remifentanil hydrochloride, quantity: 5.5 iu/mg (equivalent: remifentanil, qty 5 mg) - injection, powder for - excipient ingredients: glycine; nitrogen; hydrochloric acid - -as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults.,-as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical but not cardiac procedures in children aged 1 to 12 years.,-for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery -,when endotracheal intubation and controlled ventilation are anticipated.,-for provision of analgesia and sedation in mechanically ventilated intensive care patients.